Research Analysts’ Weekly Ratings Changes for MiniMed Group (MMED)

A number of firms have modified their ratings and price targets on shares of MiniMed Group (NASDAQ: MMED) recently:

• 9/9/2026 – MiniMed Group was upgraded by Weiss Ratings from “sell (d-)” to “sell (d)”.
• 9/3/2026 – MiniMed Group had its price target raised by Morgan Stanley from $19.00 to $21.00. They now have an “overweight” rating on the stock.
• 9/2/2026 – MiniMed Group had its price target raised by Citigroup Inc. from $23.00 to $26.00. They now have a “buy” rating on the stock.
• 9/2/2026 – MiniMed Group had its price target raised by Wells Fargo & Company from $22.00 to $26.00. They now have an “overweight” rating on the stock.
• 9/2/2026 – MiniMed Group had its price target raised by UBS Group AG from $25.00 to $28.00. They now have a “buy” rating on the stock.
• 9/2/2026 – MiniMed Group had its price target raised by Mizuho from $21.00 to $26.00. They now have an “outperform” rating on the stock.
• 9/2/2026 – MiniMed Group had its price target raised by Bank of America Corporation from $24.00 to $28.00. They now have a “buy” rating on the stock.
• 9/1/2026 – MiniMed Group had its price target raised by BTIG Research from $25.00 to $28.00. They now have a “buy” rating on the stock.
• 7/28/2026 – MiniMed Group is now covered by UBS Group AG. They set a “buy” rating and a $25.00 price target on the stock.
• 7/20/2026 – MiniMed Group was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.